BMSICL

Bihar Medical Services & Infrastructure Corporation Limited
5th floor, Biscomaun Bhavan, Gandhi Maidan, Patna 800 001
Phone: +91 612 2219634; Fax: +91 612 2219635
www.bmsicl.gov.in

CORRIGENDUM

Re-Tender for rate contract and supply of drugs for treatment of Cancer for different healthcare facilities of state of Bihar

Notice Inviting Tender Ref No. BMSIC/DRUGS/16-10 **Dated: 03-03-2017**

(Only through E- Tender on website:-**www.eproc.bihar.gov.in**)

Bihar Medical Services and Infrastructure Corporation Limited (BMSICL) had invited E-Bids from the interested parties for "**Re-Tender for rate contract and supply of Drugs for treatment of Cancer for different healthcare facilities of State of Bihar"**, vide Notice Inviting Tender No.-BMSIC/DRUGS/16-10. Detailed tender document containing eligibility criteria, selection mechanism, other terms and conditions are available on the website **www.eproc.bihar.gov.in.** As per minutes of pre-Bid meeting dated 07-02-2017 the amendments in the bid documents are annexed herewith as Annexure 'A' and accordingly the tender schedule is being revised as follows.

Tender Schedule

Tender Reference No.	**BMSIC/DRUGS/16-10**
Date and time for downloading of bid document	**16th January 2017 from 1000 Hrs. to 10th March 2017 till 1500 Hrs.**
Last date and time of submission of online bids	**13th March 2017 by 1500 Hrs.**
Last date and time for submission of original bid documents with EMD and Tender Fees	**15th March 2017 till 1500 Hrs.**
Date, Time and Place of opening of Technical Bid	**15th March 2017 (at 1530 Hrs.) on the website of www.eproc.bihar.gov.in in the office of BMSICL**
Date and time of opening of Financial Bids	**To be announced later on www.bmsicl.gov.in and www.eproc.bihar.gov.in**
Validity of Tender	**180 Days**
Cost of the tender document	**Rs. 10000/- (Ten Thousand only) Non-refundable.**
Bid Processing Fee	**Rs 1150(One thousand one hundred fifty only)/-**

Sd/-
GM (Procurement)
BMSICL

ANNEXURE- 'A'

PRE BID MEETING QUERY MINUTES

After perusal of and deliberations over the suggestions received in Pre-Bid meeting dated 24-01-2017 in tender no.-BMSIC/DRUGS/16-10, the committee in its meeting dated 07-02-2017 unanimously recommended the following Amendments/Clarifications:-

S.N.	Clause as per NIT	Present Clause as per NIT	Amended
1.	Clause 3 (f)	Bidders must have :- • Minimum three years old valid Manufacturing License of the product quoted with latest license renewal certificate. • Approved product list as per the license issued for quoted drugs for minimum three years. • Manufacturing License along with approved product list must be valid till the last date of the submission of tender. • In Case of those drugs which are notified first time in IP 2014 then	Bidders must have :- • Minimum three years old valid Manufacturing License of the product quoted with latest license renewal certificate. • Approved product list as per the license issued for quoted drugs for minimum three years. • Manufacturing License along with approved product list must be valid till the last date of the submission of tender. • In Case of those drugs which are notified first time in IP 2014 then Manufacturing and Marketing license should be in any official compendium (USP/BP/IP) along with current valid License in IP in continuation. • Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a

		Manufacturing and Marketing license should be in any official compendium (USP/BP/IP) along with current valid License in IP in continuation. • Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of **'New Drug'** as defined by CDSCO (Central Drugs Standard Control Organisation). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed. • For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect.	Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of **'New Drug'** as defined by CDSCO (Central Drugs Standard Control Organisation). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed. • For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect. • FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it. **The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall apply.**

		• FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.	
2.	Annexure – I(Tendered Product list)	1. Doxorubicin IP 2mg/ml Injection. 3. Carboplatin IP 100 IU/ml Injection. 9. Gemcitabine 200 mg/5ml Injection.	1(a). Doxorubicin IP Injection 2 mg/ml-10 mg vial. 1(b). Doxorubicin IP Injection 2 mg/ml-50 mg vial. 1(c). Doxorubicin IP Injection 2 mg/ml-100 mg vial. 3(a). Carboplatin IP Injection- 10mg/ml-150mg Vial. 3(b). Carboplatin IP Injection- 10mg/ml-450mg Vial. 9(a). Gemcitabine IP Injection 40 mg/ml -100 mg Vial. 9(b). Gemcitabine IP Injection 40 mg/ml -1000 mg Vial.

Sd/-